 TRACON Pharmaceuticals Inc said it has upsized its previously announced bought deal offering of common stock to 15 million from 10 million due to increased demand to advance the continued clinical development of potential cancer drug envafolimab. The San Diego company, which utilizes a capital-efficient product development platform to develop its clinical-stage pipeline of cancer therapies, said that due to demand, the underwriter has agreed to increase the size of the public offering and purchase on a firm commitment basis of 3,926,702 shares at a price of 3.82 per share, less underwriting discounts, and commissions. 